BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result

We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing stocks on Monday.

BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the stellar results of its final clinical trial for the study of BBP-418 in patients with a rare genetic condition that causes muscles to weaken, affects breathing problems, and causes heart issues.

In intra-day trading, the stock surged to its highest price of $65 before trimming gains to end the day just up by 17.14 percent at $63.56 apiece.

BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result

In a statement, BridgeBio Pharma, Inc. (NASDAQ:BBIO) said its drug candidate, BBP-418, showed major improvements in muscle and lung function in patients during the phase 3 clinical trial.

Among the salient results are the restoration of a key muscle protein often missing in individuals with the said disease and enabling patients to walk faster and have a better lung capacity, as compared with those who took the placebo.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) added that BBP-418 was well-tolerated with no major safety findings observed.

Following the results, BridgeBio Pharma, Inc. (NASDAQ:BBIO) is set to meet with the Food and Drug Administration by the end of the year to discuss the data. A New Drug Application is targeted for submission within the first half of 2026.

While we acknowledge the risk and potential of BBIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BBIO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.